Development of Pacific Shuanglin Bio-pharmacy Co attracting industry attention
By ZHENG YIRAN |
chinadaily.com.cn |
Updated: 2025-09-12 18:05
Share
Share - WeChat
However, raw plasma has become a bottleneck restricting product supply and the development of blood product enterprises. In order to rapidly increase the scale of raw plasma, the company actively promotes outward expansion and completes strategic restructuring work and cooperation with Xinjiang Deyuan Biological Engineering Co Ltd.
Through endogenous growth and external expansion, Pacific Shuanglin realized rapid development during the 14th Five-Year Plan period. In 2024, the company's sales revenue reached nearly 2.7 billion yuan ($379.1 million), and net profit reached 745 million yuan.
Between 2020 and 2024, compound annual growth rate of the company's sales revenue was 26.1 percent, while that of net profit reached 42.11 percent.
